PT - JOURNAL ARTICLE AU - Schultheiß, Christoph AU - Willscher, Edith AU - Paschold, Lisa AU - Gottschick, Cornelia AU - Klee, Bianca AU - Bosurgi, Lidia AU - Dutzmann, Jochen AU - Sedding, Daniel AU - Frese, Thomas AU - Girndt, Matthias AU - Höll, Jessica I. AU - Gekle, Michael AU - Mikolajczyk, Rafael AU - Binder, Mascha TI - Liquid biomarkers of macrophage dysregulation and circulating spike protein illustrate the biological heterogeneity in patients with post-acute sequelae of COVID-19 AID - 10.1101/2022.09.18.22280022 DP - 2022 Jan 01 TA - medRxiv PG - 2022.09.18.22280022 4099 - http://medrxiv.org/content/early/2022/09/19/2022.09.18.22280022.short 4100 - http://medrxiv.org/content/early/2022/09/19/2022.09.18.22280022.full AB - Post-acute sequelae of COVID-19 (PASC) are long-term consequences of SARS-CoV-2 infection that can substantially impair quality of life. Underlying mechanisms ranging from persistent virus to innate and adaptive immune dysregulation have been discussed. Here, we profiled plasma of 181 individuals from the cohort study for digital health research in Germany (DigiHero) including individuals after mild to moderate COVID-19 with or without PASC and uninfected controls. We focused on soluble factors related to monocyte/macrophage biology and on circulating SARS-CoV-2 spike (S1) protein as potential biomarker for persistent viral reservoirs. At a median time of eight months after infection, we found pronounced dysregulation in almost all tested soluble factors including both pro-inflammatory and pro-fibrotic cytokines. These perturbations were remarkably independent of ongoing symptoms, but further correlation and regression analyses suggested PASC specific patterns involving CCL2/MCP-1 and IL-8 as well as long-term persistence of high IL-5 and IL-17F levels. None of the analyzed factors correlated with the detectability or levels of circulating S1 indicating that this represents an independent subset of patients with PASC. This data confirms prior evidence of immune dysregulation and persistence of viral protein in PASC and illustrates its biological heterogeneity that still awaits correlation with clinically defined PASC subtypes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partially funded by the Med- ical Faculty of the Martin-Luther-University Halle-Wittenberg.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB of the University Hospital Halle (Saale), Germany, gave ethical approval for this work,I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.